- Home
- IONS vs LRN Comparison
IONS vs LRN Comparison
Compare IONS & LRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- LRN
- Stock Information
- Founded
- IONS 1989
- LRN 2000
- Country
- IONS United States
- LRN United States
- Employees
- IONS N/A
- LRN N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- LRN Other Consumer Services
- Sector
- IONS Health Care
- LRN Real Estate
- Exchange
- IONS Nasdaq
- LRN Nasdaq
- Market Cap
- IONS 4.6B
- LRN 5.4B
- IPO Year
- IONS 1991
- LRN 2007
- Fundamental
- Price
- IONS $32.26
- LRN $156.37
- Analyst Decision
- IONS Buy
- LRN Buy
- Analyst Count
- IONS 18
- LRN 5
- Target Price
- IONS $57.41
- LRN $133.40
- AVG Volume (30 Days)
- IONS 1.7M
- LRN 815.9K
- Earning Date
- IONS 04-30-2025
- LRN 04-29-2025
- Dividend Yield
- IONS N/A
- LRN N/A
- EPS Growth
- IONS N/A
- LRN 49.70
- EPS
- IONS N/A
- LRN 6.39
- Revenue
- IONS $717,253,000.00
- LRN $2,285,853,000.00
- Revenue This Year
- IONS N/A
- LRN $15.83
- Revenue Next Year
- IONS $27.39
- LRN $6.94
- P/E Ratio
- IONS N/A
- LRN $24.47
- Revenue Growth
- IONS N/A
- LRN 14.90
- 52 Week Low
- IONS $23.95
- LRN $63.25
- 52 Week High
- IONS $52.34
- LRN $162.30
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- LRN 70.57
- Support Level
- IONS $31.66
- LRN $156.24
- Resistance Level
- IONS $33.98
- LRN $160.39
- Average True Range (ATR)
- IONS 1.30
- LRN 5.53
- MACD
- IONS 0.41
- LRN 1.27
- Stochastic Oscillator
- IONS 68.84
- LRN 79.16
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About LRN Stride Inc.
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional, and Private Pay Schools and Other.